Histone Deacetylase Inhibitors: Emerging Anticancer Therapeutic Agents?

2005 ◽  
Vol 7 ◽  
pp. S19-S30 ◽  
Author(s):  
Rebecca Kristeleit ◽  
Peter Fong ◽  
G. Wynne Aherne ◽  
Johann de Bono
Keyword(s):  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitors ◽  
Therapeutic Agents

Histone Deacetylase Inhibitors as Potential Therapeutic Agents for the Treatment of Malignant Mesothelioma

2013 ◽  
Vol 13 (3) ◽  
pp. 476-482
Author(s):  
Patroklos Katafygiotis ◽  
Constantinos Giaginis ◽  
Efstratios Patsouris ◽  
Stamatios Theocharis
Keyword(s):  
Histone Deacetylase ◽  
Malignant Mesothelioma ◽  
Histone Deacetylase Inhibitors ◽  
Therapeutic Agents

scholarly journals Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

Blood ◽  
2013 ◽  
Vol 121 (8) ◽  
pp. 1296-1303 ◽  
Author(s):  
Irene M. Ghobrial ◽  
Federico Campigotto ◽  
Timothy J. Murphy ◽  
Erica N. Boswell ◽  
Ranjit Banwait ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitors ◽  
Single Agent ◽  
Therapeutic Agents ◽  
Phase 2 ◽  
Phase 2 Trial ◽  
Deacetylase Inhibitor ◽  
Key Points ◽  
Phase 2 Clinical Trial ◽  
Active Class

Key Points Presents the data from a phase 2 clinical trial of panobinostat in patients with relapsed WM. Establishes a role for histone deacetylase inhibitors as an active class of therapeutic agents in WM.

Histone Deacetylase Inhibitors as Potential Therapeutic Agents for the Treatment of Malignant Mesothelioma

2013 ◽  
Vol 13 (3) ◽  
pp. 476-482 ◽  
Author(s):  
Patroklos Katafygiotis ◽  
Constantinos Giaginis ◽  
Efstratios Patsouris ◽  
Stamatios Theocharis
Keyword(s):  
Histone Deacetylase ◽  
Malignant Mesothelioma ◽  
Histone Deacetylase Inhibitors ◽  
Therapeutic Agents

scholarly journals A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma

2019 ◽  
Vol 8 (1) ◽  
Author(s):  
Shanshan Zhang ◽  
Zhaojian Gong ◽  
Peter O. Oladimeji ◽  
Duane G. Currier ◽  
Qipan Deng ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
High Throughput ◽  
High Throughput Screening ◽  
Cell Cycle Progression ◽  
Histone Deacetylase Inhibitors ◽  
Tumor Development ◽  
Treatment Strategies ◽  
Therapeutic Agents ◽  
Current Treatment ◽  
Cell Viability Assay

Abstract Background Medulloblastoma is the most frequently occurring malignant brain tumor in children. Current treatment strategies for medulloblastoma include aggressive surgery, cranio-spinal irradiation and adjuvant chemotherapy. Because current treatments can cause severe long-term side effects and are not curative, successful treatment remains a challenge. Methods In this study, we employed a high-throughput cell viability assay to screen 12,800 compounds and to identify drug candidates with anti-proliferative properties for medulloblastoma cells. We also tested these compounds for attenuating medulloblastoma tumor development using mouse xenografts. Results We identified two histone deacetylase inhibitors (dacinostat and quisinostat) with anti-proliferative properties for medulloblastoma cells. We showed that both compounds induce cytotoxicity, trigger cell apoptosis, and block cell cycle progression at the G2/M phase. In addition, dacinostat and quisinostat attenuated xenograft medulloblastoma growth in mice. Conclusions Our findings suggest that histone deacetylase inhibitors are potent therapeutic agents against medulloblastoma.

Sign in / Sign up

Export Citation Format

Share Document